- Guido Guenther Heinrich Gerken, MD
- Director emeritus of the Department of Gastroenterology and Hepatology, University of Essen, Essen, Germany.
Ethics committee of the European Association for the Study of the Liver (EASL)
Website | E-mail
Special Issue Introduction
Hepatocellular carcinoma (HCC) is the sixth most frequent malignancy and the second most common cause of cancer-related death worldwide. However, HCC is a major global health problem with geographic, ethnic and racial variation worldwide. In general HCC develops on the basis of a chronic liver disease, mostly associated to liver cirrhosis as the most important pathogenetic risk factor. There are several viral, non viral, metabolic, environmental and genetic factors, etc. as risk factors for the development of HCC, but currently NAFLD/NASH are significantly increasing as leading HCC triggering factor worldwide.
For our special issue, we focus on hepatoma risk factors, and topics should be discussed such as the importance of HCV, HBV, NAFLD/NASH/metabolic syndrome, hereditary disease including Hemochromatosis/Wilson’s disease, Alcoholic Steatohepatitis, autoimmune diseases including autoimmune hepatitis, Primary Biliary Cholangitis, Primary Sclerosing Cholangitis, aflatoxin/nicotine exposure, in addition to prevention strategies (vaccination, nutrition, treatment) and the value of biomarkers (AFP) in the early diagnostic and prediction in patients at risk for HCC.
Participants1. Mohamed M. El Kabany Pfleger Liver Institute, University of California Los Angeles, Los Angeles, USA.
2. Pierluigi Toniutto Hepatology and Liver Transplant Unit, Department of Medical Area, Udine University Hospital, Udine, Italy.
3. Jan Best Department of Gastroenterology, Hepatology and Infectiology, University Hospital Magdeburg, Magedurg, Germany.
4. Hideo Baba & Suzan Schwertheim University Hospital of Essen, University of Duisburg-Essen, Essen, Germany.
5. Yong Chen Department of Hepatobiliary Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
6. Alberto Zanetto Gastroenterology and Multivisceral Transplant Unit, Department of Surgery, Oncology and Gastroenterology, Padua University Hospital, Padua, Italy.
7. Debra A. Guss Division of Gastroenterology and Hepatobiliary Diseases, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, USA.
8. Amedeo Lonardo Operating Unit Internal Medicine, Department of Medicine, Azienda Ospedaliero-Universitaria Modena, Italy.
9. Monika Pazgan-Simon Department of Infectious Diseases and Hepatology, Wroclaw Medical University, 50-367 Wrocław, Poland.
10. Monika Pazgan-Simon Department of Radiology, West China Hospital of Sichuan University, Chengdu, China.
11. Ke Qing Shi Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
12. Dar-In Tai Department of Gastroenterology and Hepatology, Chang Gung Memorial Hospital at Linkou, Chang Gung University, Taoyuan, Taiwan.
13. Chaoliu Dai & Chunbo Yang Department of Otolaryngology Head and Neck Surgery, Shengjing Hospital of China Medical University, Shenyang, China.
14. Massimo Colombo Department of Medicine, Center for Translational Research in Hepatology, Clinical and Research Center Humanitas Hospital, Rozzano, Italy; EASL International Liver Foundation, Geneva, Switzerland.
The list is arranged in no particular order.
Submission Deadline31 May 2020